Bästa Retina Today podcaster (2024)

1
Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR 28:42

1d ago28:42

28:42

Tens of thousands of real-world geographic atrophy patients were analyzed in a retrospective database study. How did GA progress—and how do these data inform our understanding of GA? Ted Leng, MD, stopped by the show to share the findings from his research on the natural history of GA, which he recently delivered on the podium in Lisbon. And Michae…

1
The Future of Vision Technology 38:45

6d ago38:45

38:45

In this episode of the OIS Podcast, host Rob Rothman sits down with Jay Cormier, CEO of Eyedaptic, to explore innovative solutions for individuals with vision loss. They discuss Eyedaptic's groundbreaking technology and its impact on enhancing daily life for those with visual impairments. Key Highlights: Insight into the inspiration behind Eyedapti…

1
ASRS Milestones in Retina: History of Anti-VEGF 49:58

21d ago49:58

49:58

Join us for an extraordinary Milestones in Retina expert panel discussion detailing the discovery and evolution of a treatment that truly revolutionized the field of retina and the lives of patients around the world – virtually overnight. That therapy is, of course, anti-VEGF. It goes without saying that there is an army of researchers, clinicians,…

1
New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAO 16:15

23d ago16:15

16:15

What is the relationship between retinal artery occlusion (RAO) and death, stroke, or myocardial infarction? Moderator Katherine Talcott, MD, is joined by Kyle Kovacs, MD, and Phoebe Mellen, MD, to explore the latest contribution to the literature on this topic. After the break, they discuss how best to manage patients who present to the clinic wit…

1
ASRS ’24: C1q Inhibition and Metformin for AMD 23:43

1M ago23:43

23:43

Could inhibition of C1q effectively halt the progression of GA? Joel Pearlman, MD, PhD, sat down to discuss findings from the phase 2 ARCHER study, which evaluated ANX007 (Annexon) in patients with GA. He tells us what happened when patients were dosed with ANX007 for 1 year—and what occurred when patients stopped receiving treatment. And later, Di…

1
New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF Therapy 17:41

1M ago17:41

17:41

Does switching long-term wet AMD patients to faricimab (Vabysmo, Genentech/Roche) result in meaningful change to disease presentation? Join New Retina Radio Journal Club host Ben Young, MD, MS, and panelists Lediana Goduni, MD, and Josh Uhr, MD, as they break down a recent real-world study published in the literature. After the break, they review w…

1
Revolutionizing Corneal Health 29:48

2M ago29:48

29:48

In this week’s OIS Podcast episode, Host Dr. Robert Rothman sits down with Almog Aley-Raz, CEO of CorNeat Vision, for a fascinating discussion. They cover: Almog’s career journey from Israel to the U.S. How a mountain biking trip with an ophthalmologist sparked the idea for CorNeat Vision Corneal blindness as a global issue and the need for better …

1
The Changing Reimbursement Landscape for Retina Practices and How to Keep Up 41:26

2M ago41:26

41:26

Take a listen to the latest episode of ASOA EyeTalks Radio, presented by ASOA Gold Strategic Business Partner, SamaCare. ASOA chats with 30+ year revenue cycle management expert Erin Bishop, RCM COE Manager at EyeCare Partners, and 25+ year medical technology veteran Kip Theno, VP of Provider Partnerships at SamaCare about challenges retina practic…

1
ASRS ’24: PAVILION at 100 Weeks 7:47

2M ago7:47

7:47

The Port Delivery System with Ranibizumab (PDS; Susvimo, Genentech) was shown to be effective for wet AMD treatment. What did the PAVILION study find when it came to treating diabetic retinopathy out to 100 weeks? Margaret Chang, MD, summarized the PAVILION study’s 2-year safety and efficacy findings regarding the PDS in patients with DR but no DME…

1
Venture Insights On Retinal Innovation 30:00

2M ago30:00

30:00

Exciting insights from the OIS Retina Panel! Moderated by Dr. Emmett Cunningham, this discussion dives deep into the current state of ophthalmology investment and innovation. Panelists, Anna Chen, Adit Ghosh, Dr. Firas Rahhal and Caroline Stout shared their perspectives on the evolving landscape, highlighting both opportunities and challenges in th…

1
ASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings 16:16

2M ago16:16

16:16

Is avacincaptad pegol (Izervay, Astellas) effective in patients with major ellipsoid zone attenuation at baseline? Katherine Talcott, MD, stopped by our studio in Stockholm during ASRS with a top-line summary of her lecture at this year’s meeting. And Sunir Garg, MD, joined us for a conversation about the GALE study, which assessed 36 months of con…

1
The AI Revolution in Healthcare with Albert Katz, Co-Founder & CEO at Flagler Health 38:32

2M ago38:32

38:32

This is the Healthcare Executive Insights Podcast presented by The Macallan Group. In this episode, Albert Katz, CEO & Co-Founder of Flagler Health, explores how their AI solutions are transforming musculoskeletal clinics by enhancing patient care and operational efficiency. Flagler Health's innovative AI tools streamline patient triaging and sched…

1
The View from the Street 27:31

3M ago27:31

27:31

Don’t miss the OIS Retina Panel, moderated by Dr. Pravin Dugel, “The View from the Street.” Join Dr. Anupam Dalal, Andrew Gitkin, and Cameron Taylor as they discuss the latest in ophthalmology, including: Current Challenges: Few blockbuster drugs and limited M&A activity Opportunities: Growth potential from recent GA therapy successes Strategic Ins…

1
New Retina Radio Journal Club w/ VBS: Risk Factors for Switching from Bevacizumab to Aflibercept in Protocol AC 19:37

3M ago19:37

19:37

Patients with DME in DRCR Retina Network Protocol AC were switched from bevacizumab to aflibercept if they met specific switch criteria. Where there any baseline factors that predicted a switch? Moderator Rebecca Soares, MD, sits down with panelists Matt Starr, MD, and Nikisha Kothari, MD, to review this study, ask whether the findings are clinical…

1
ASRS Leaders and Legends Interview: Mark S. Blumenkranz, MD 32:20

3M ago32:20

32:20

The History of Retina is pleased to share this Leaders & Legends interview featuring the extraordinary life and career of Mark Blumenkranz, MD. Dr. Blumenkranz is the HU Smead Professor Emeritus and co-director of the Ophthalmic Innovation Program at the Byers Eye Institute at Stanford University School of Medicine. In addition, he serves as manage…

1
ASRS Leaders and Legends Interview: Emily Y. Chew, MD 27:54

3M ago27:54

27:54

Emily Y. Chew, MD, is director of the Division of Epidemiology and Clinical Applications and deputy clinical director of the National Eye Institute (NEI). She is also a senior investigator and Chief of the NEI’s Clinical Trials Branch. In this Leaders & Legends interview Dr. Chew shares fascinating experiences and perspectives from her extraordinar…

1
ASRS Leaders and Legends Interview: Eugene de Juan, Jr., MD, FASRS 29:41

3M ago29:41

29:41

Unlike most kids, Eugene de Juan, Jr., preferred his toys broken. Fascinated by his ophthalmologist father’s many gadgets and his grandfather’s workshop, Gene discovered his passion for fixing things at an early age. He went on to complete his ophthalmology and vitreoretinal training at world-class institutions including the Johns Hopkins Universit…

1
Celebrating 400 Episodes of OIS 53:41

3M ago53:41

53:41

Discover the milestone 400th episode of the OIS podcast with Dr. Firas Rahhal and Dr. Robert Rothman, where they explore the impact of Ophthalmology Innovation Summit (OIS) on the investment ecosystem: Journey of OIS Rich Insights Collaboration Clinical Mastery Long-Term Relationships Humor and Admiration Future of Ophthalmology Tune in to this epi…

1
From Trials to the Clinic: Using a Therapy With a Novel MOA to Treat Patients With DME 29:41

3M ago29:41

29:41

One of the challenges associated with current anti-VEGF therapies for the management of DME is the need for frequent injections and the potential impact on adherence and vision outcomes. Join Dr. John Kitchens and Dr. Maria Berrocal as they share their experiences treating their DME patients using a therapy with a novel mechanism of action, and how…

1
New Retina Radio Journal Club w/ VBS: RVOs During the COVID Pandemic 15:15

4M ago15:15

15:15

What did a review of the AAO IRIS Registry reveal about the rates of retinal vein occlusion (RVO) during the COVID-19 pandemic? Moderator Katherine Talcott, MD, sits down with Phoebe Mellen, MD, and Kyle Kovacs, MD, to review the study's conclusion that RVO rates did not increase during the pandemic, discuss challenges about talking to patients see…

1
Advances in Corneal Health 8:33

4M ago8:33

8:33

In this episode of Eye on Innovation Podcast, Carey Powers delves into the latest advancements in corneal crosslinking technology with expert guest Dr. Deepinder Dhaliwal. Dr. Dhaliwal, a renowned professor of ophthalmology at the University of Pittsburgh School of Medicine and director of refractive surgery at the UPMC Vision Institute, shares her…

1
A Treatment With a Novel MOA for Patients With nAMD and DME: Perspectives From the Real World 34:24

4M ago34:24

34:24

Recent studies have proven the therapeutic viability of a different approach in treating retinal vascular diseases. Join Dr. John Kitchens, Dr. Margaret Chang, and Dr. David Chin Yee as they discuss their clinical experiences using a therapy with a novel mechanism of action in patients with nAMD and DME. And, learn how they approach managing patien…

1
AMD and DME Applications in the Retina Practice: Real-world Data 21:08

4M ago21:08

21:08

In the second episode of this 2-part series, moderator Paul Hahn, MD, PhD, and panelists Durga Borkar, MD, MMCi, and Ted Leng, MD, turn to the findings of FARETINA-AMD and FARETINA-DME, which rely on real-world outcomes as documented in the AAO IRIS Registry. What can retina specialists learn from these studies, and how might these studies' finding…

1
Revolutionizing Eye Care 41:10

4M ago41:10

41:10

In our latest episode, host Dr. Rob Rothman interviews Greg Kunst, CEO of Aurion Biotech, to delve into the forefront of cell therapy for corneal disease. Join us to discover: Greg's journey from pivotal roles at Alcon and Glaukos to leading Aurion Biotech The innovative allogenic cell therapy technology developed by Aurion How this technology addr…

1
The MSO Model You Have Never Heard Of with Will Vanderveer of Redefine Healthcare 19:29

4M ago19:29

19:29

This is the Healthcare Executive Insights Podcast presented by The Macallan Group. In this episode, we speak with Will Vanderveer, CEO at Redefine Healthcare, and explore how Redefine Healthcare is revolutionizing the landscape for independent physicians. Unlike traditional management service organizations (MSOs), Redefine Healthcare operates witho…

1
ARVO 2024 Coverage: UWF Leakage in Protocol AA, Machine Learning, and GA's Link to Anxiety/Depression 22:55

4M ago22:55

22:55

Protocol AA might be complete—but analysis of its data is far from over. What did that study’s data tell us about the relationship between leakage and DR severity? Justis Ehlers, MD, breaks down what he and his team uncovered when examining ultra-widefield images from Protocol AA, and helps us understand how machine learning might be used in future…

1
New Retina Radio Journal Club with VBS: New Retina Radio Journal Club with VBS: Is Buckling Effective for RRD in Patients at Risk for PVR? 13:57

4M ago13:57

13:57

How do outcomes differ for RRD patients at risk of PVR following PPV alone or combined PPV/scleral buckling? Moderator David Xu, MD, hears from panelists Barton Blackorby, MD, and Prethy Rao, MD, MPH, about a recent peer-reviewed paper published in Ophthalmology Retina covering surgical outcomes of patients with RRD who were considered high risk fo…

1
Todays Therapies are Not Sufficient: A Marketplace Ripe for Innovation 36:58

5M ago36:58

36:58

This week's OIS Podcast features a compelling panel discussion from the Dry Horizons Symposium co-presented by Ora and OIS, held on May 3 in Seattle. The panel, comprising leading experts in ophthalmology and dry eye research, covered essential topics in the field: 🔹Advancements in Diagnostics: Insights into new tools and technologies for more accu…

1
ARVO 2024 Coverage: ≥20-week Dosing in PULSAR and TENAYA/LUCERNE 16:00

5M ago16:00

16:00

Could next-generation anti-VEGF agents such as faricimab (Vabysmo, Genentech/Roche) and high-dose aflibercept (Eylea HD, Regeneron) be dosed as infrequently as every 20 weeks without sacrificing efficacy? And even if there are data that suggest that finding, would anyone actually adopt an interval that long in wet AMD patients? Philip Storey, MD, f…

1
ASRS Leaders and Legends Interview: Drs. Susan B. and Neil M. Bressler 39:46

5M ago39:46

39:46

Leaders & Legends is pleased to share an interview with a true dynamic duo in retina: Drs. Susan and Neil Bressler. Susan and Neil’s personal and professional partnership started in their early days at John Hopkins medical school and, with thoughtful intention, they set out to build their life and careers together. They both pursued ophthalmology r…

1
AI and Robotics Transforming Retina Medicine 13:50

5M ago13:50

13:50

Explore the cutting-edge world of ophthalmology with the Eye on Innovation Podcast. In the latest episode, Carey Powers hosts Dr. Rishi Singh and Dr. Michael Singer as they delve into how AI and robotics are transforming retina medicine, bringing unprecedented changes to diagnosis, clinical trials, and patient care. This insightful discussion provi…

1
GA Options in Clinical Therapy, Part 2: Real-world Cases in GA 17:20

5M ago17:20

17:20

David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, return for the second episode in this podcast miniseries, in which they review a trio of real-world GA cases, explore what early responses to treatment look like, and ask how to address GA in the presence of wet AMD.Av Retina Today

1
GA Options in Clinical Therapy, Part 1: Patient Selection and Treatment Strategies 23:42

5M ago23:42

23:42

Join David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, as they assess which clinical and non-clinical characteristics drive their decision-making in patients with geographic atrophy (GA). After the break, Dr. Faia shares a real-world case from her clinic in which a patient who was lost to follow-up returns to consider treatment.…

1
AMD and DME Applications in the Retina Practice: RCT Comparison 21:13

5M ago21:13

21:13

What conclusions can be drawn from a cross-trial comparison of randomized clinical trials assessing the safety and efficacy of anti-VEGF agents used in the treatment of AMD and DME? Paul Hahn, MD, PhD, sits down with Durga Borkar, MD, MMCi, and Ted Leng, MD, to review a recent presentation by Dr. Leng on this topic, and to examine the clinical rele…

1
Exploring the FDA 43:06

6M ago43:06

43:06

In this compelling OIS podcast episode, host Dr. Rob Rothman engages in an insightful conversation with Dr. Malvina Eydelman, the Director of the FDA's Office of Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices. Delve into Malvina's unique career journey and discover how her diverse background in engineering and ophthalmology has influe…

1
The State of Biosimilars: Integration of Biosimilars into a Retina Practice 22:03

6M ago22:03

22:03

Biosimilars in retina are here. How are practices integrating them into their clinics? And how do they navigate issues around payer policy, protocol changes, and ensuring continuity of care? Moderator John Kitchens, MD, sits down with retina specialist Dave Brown, MD, and Kristin Yockus, the VP of Process Integrations at Retina Consultants of Ameri…

1
New Retina Radio Journal Club with VBS: Comparison of Antiseptics Use for IVT 15:48

6M ago15:48

15:48

How do endophthalmitis rates after intravitreal injection differ after using povidone-iodine compared with chlorhexidine? Moderator Sruthi Arepalli, MD, hears from panelists Vaidehi Dedania, MD, and Rebecca Soares, MD, MPH, about a recent peer-reviewed retrospective cohort study on this topic. After the break, the trio discuss how to manage patient…

1
Improving Patient Care Through SOPs and Innovative Technologies with Kelly Ladd at Piedmont Internal Medicine 43:48

6M ago43:48

43:48

This is the Healthcare Executive Insights Podcast presented by The Macallan Group. In Episode 51, we speak with Kelly Ladd, CEO of Piedmont Internal Medicine. Kelly has extensive experience in healthcare management, particularly in private physician practices. She shares her journey and insights with us, highlighting the importance of adaptability …

1
Developing a Culture to Thrive and Prevent Burnout with Quinn McCullough at Scottsdale Detox Center and The Hope House 50:44

6M ago50:44

50:44

This is the Healthcare Executive Insights Podcast presented by The Macallan Group. In Episode 52, we sit down with Quinn Davidson, who shares the innovative approach of Scottdale Detox Center and The Hope House in tackling substance abuse. Their focus on individualized and comfortable care in a holistic, trauma-informed environment aims to address …

Podcaster värda att lyssna på

Retina Today podcaster

Podcaster värda att lyssna på

Snabbguide